31.66 USD
▲+2.24+7.61%
盘后 31.68 +0.06%
2026-09-15
市值
$550.91M
市盈率
—
EPS
-13.18
股息率
—
52 周区间
17.31 – 39.60
成交量
162.61K
Beta
—
目标价
57.00
52W 低 17.3152W 高 39.60
价格走势
公司简介
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and ...